You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails

Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However, not all patients respond to first-line therapy, and some may need to discontinue due to side effects or disease progression.

In this webinar, Dr. Allison Betof, MD, PhD, Director of the Melanoma Program at Stanford University, and Melissa Wilson, PA-C, MPAS, discuss what patients should know and do when initial melanoma treatment fails.

Understanding Why Therapy Fails

There are two primary reasons for stopping treatment:

1. Progression: The therapy no longer controls tumor growth.
2. Toxicity: Side effects make continued treatment unsafe.

Important insight: Stopping due to toxicity doesn’t always require immediate alternative therapy. Sometimes, the immune system remains active for months or years, keeping the disease under control.

How to Know if Your Therapy is Working

• Imaging: CT scans, PET scans, and MRI are the most reliable methods to monitor melanoma response.
• Blood markers: LDH and ctDNA are discussed but currently not reliable for routine monitoring in melanoma.
• Biopsy: Occasionally required to differentiate between inflammation and true progression.

Next Steps After First-Line Therapy

1. Molecular Profiling

• Ask if next-generation sequencing (NGS) has been done.
• Mutations beyond BRAF (e.g., NRAS, KIT, RET) may be actionable with targeted therapy or clinical trials.

2. Clinical Trials

• Explore available trials — cell therapy, immunotherapy, or targeted therapy trials.
• Early enrollment often leads to better outcomes.
• Second or third opinions at melanoma centers with multiple trial options can provide critical guidance.

3. Tumor-Infiltrating Lymphocyte (TIL) Therapy

• TIL therapy uses engineered T-cells to attack melanoma directly.
• Optimal outcomes occur as early as possible after progression on checkpoint inhibitors.
• Myths dispelled:
  • “After TIL, nothing else works” – false.
  • “I am ineligible for future trials after TIL” – false.

Special Considerations

• Rechallenge: Some patients may safely receive checkpoint inhibitors after TIL therapy or repeat TIL if appropriate.
• Brain metastases: Certain cell therapies, immunotherapy combinations, and targeted agents can penetrate the brain, though careful monitoring is essential.
• Mucosal melanoma: Lower response rates exist, but selected patients may still benefit from clinical trials or TIL therapy.

Maintaining Quality of Life

Even while exploring advanced therapies, focus on physical and emotional well-being:

• Exercise (~75 minutes/week) and proper nutrition (high protein, high fiber).
• Use center resources: social work, occupational therapy, nutrition, transportation support.
• Caregiver support is also crucial — maintaining patient and family wellness improves treatment outcomes.

Key Takeaways

• First-line failure is not the end — multiple lines of therapy exist.
• Imaging is the most dependable tool for monitoring treatment efficacy.
• Ask about molecular profiling and clinical trials early.
• TIL therapy can be highly effective when used promptly after progression.
• Quality of life measures are vital for immune-based therapy success.

Patients with melanoma have many options even after first-line therapy fails. Staying informed, exploring clinical trials, and collaborating with melanoma experts can significantly impact outcomes. Remember: you are not out of options.

Watch the full webinar above for detailed insights and expert guidance.

---